Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company. Through these regulatory documents, investors can review how Prelude describes its business, pipeline, risks, and financial condition as it advances programs such as SMARCA2 and KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Key filings include annual reports on Form 10-K, which provide an overview of Prelude’s precision oncology strategy, target selection, collaborations, and risk factors, and quarterly reports on Form 10-Q, which update on operating expenses, cash runway, and development progress. Current reports on Form 8-K disclose material events such as the exclusive option agreement with Incyte for the JAK2V617F program, expanded arrangements with AbCellera Biologics, clinical portfolio reprioritizations, Nasdaq listing compliance updates, and changes in board or executive roles.
Investors interested in ownership and governance can also use SEC filings to track equity financings, non-voting common stock issuances, and other capital structure changes described in transaction-related 8-Ks and registration statements. These documents outline terms of option agreements, securities purchase agreements, and related registration rights for Prelude’s stock.
On Stock Titan, each new PRLD filing is captured from EDGAR and paired with AI-powered summaries that highlight the most relevant points, such as pipeline focus, collaboration economics, cash position commentary, and listing status updates. This helps readers navigate lengthy reports and quickly locate information on topics like JAK2V617F program economics, SMARCA2 and KAT6A development plans, and the impact of strategic decisions on Prelude’s financial profile.
Use this page to access Prelude Therapeutics’ 10-K, 10-Q, 8-K and related filings, along with concise AI explanations that clarify technical disclosures and regulatory language for PRLD stock watchers.